Matsukiyococokara & Co. · TSE:3088

Matsukiyococokara & — Q1 FY2024 Earnings Presentation

13 slides from Matsukiyococokara &'s earnings presentation, Aug 13, 2024

  1. Slide 1: Financial Results for the Three Months Ended June 30, 2024

    Financial Results for the Three Months Ended June 30, 2024 August 13, 2023 Copyright 2024 MatsukiyoCocokara & Co. MatsukiyoCocokara & Co. All rights Reserved.

  2. Slide 2: Table of Contents

    Table of Contents Financial Summary (YoY) ・・・・・・ 3 Segment Results (YoY) ・・・・・・ 4 Segment Results (YoY) ) (Reference) ・・・・・・ 5 Excluding amortization of goodwill and trademark rights associated with the management integration with cocokarafine Inc. Net Sales by Product ・・・・・・ 6 Balance Sheet ・・・・・・

  3. Slide 3: Financial Summary (YoY)

    Financial Results for 1Q FY2024 Financial Summary (YoY)  Sales increased due to the optimal functioning of key strategies, despite a reactionary decline in COVID-19 related products  Focused on investment in human capital and system development, as well as higher SG&A expenses such as personnel co

  4. Slide 4: Segment Results (YoY)

    Financial Results for 1Q FY2024 Segment Results (YoY)  Matsumotokiyoshi Group reported an increase in sales and profit.  Cocokarafine Group reported an increase in sales and a decrease in profit. (Millions of yen) Three Months Ended Three Months Ended June 30, 2023 June 30, 2024 Change Change (Apr

  5. Slide 5: Segment Results (YoY) (Reference)

    Financial Results for 1Q FY2024 Segment Results (YoY) Excluding amortization of goodwill and trademark rights totaling 1,809 million yen Reference associated with the management integration with cocokarafine Inc. (Millions of yen) Three Months Ended Three Months Ended Change Change June 30, 2023 Jun

  6. Slide 6: Net Sales by Product

    Financial Results for 1Q FY2024 Net Sales by Product  Increase in our focused health and beauty categories  Steady implementation of key strategies led to an improvement in gross profit margin, despite a reactionary decline in COVID-19 related products (Millions of yen) Net sales Gross profit marg

  7. Slide 7: Balance Sheet

    Financial Results for 1Q FY2024 Balance Sheet  Equity ratio increased 1.2 pt from the end of the previous period（71.0％ ⇒ 72.2％） (Millions of yen) End of March, 2024 End of June, 2024 Change Current assets 370,798 364,952 (5,846) Cash and deposits 117,720 111,650 (6,070) Merchandise 138,573 143,211

  8. Slide 8: Store Openings, Closings, and Renovations in Japan

    Financial Results for 1Q FY2024 Store Openings, Closings, and Renovations in Japan  1Q Cumulative Period (Unit: No. of stores) Number of stores Openings Closings Renovations Number of stores as of March 31, 2024 in 1Q in 1Q in 1Q as of June 30, 2024 Matsumotokiyoshi Group 1,904 19 2 6 1,921 Dispens

  9. Slide 9: FY2024 Financial Forecasts

    Financial Forecasts for FY2024 FY2024 Financial Forecasts  There are no revisions to the consolidated earnings forecast announced on May 10, 2024 (Millions of yen) First Half 1H FY2023 1H FY2024 Change Change % to net sales % to net sales (amount) (%) Net sales 507,766 515,000 7,233 1.4 Gross profi

  10. Slide 10: Quarterly Consolidated Financial Results

    【Appendix】 Financial Results for 1Q FY2024 Quarterly Consolidated Financial Results FY2023 FY2024 （Millions of yen/%） 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Net sales 248,222 259,544 262,566 252,197 1,022,531 259,749 Gross profit 84,199 89,627 91,074 89,197 354,097 89,241 Gross profit margin 33

  11. Slide 11: Quarterly Segment Results

    【Appendix】 Financial Results for 1Q FY2024 Quarterly Segment Results FY2023 FY2024 （Millions of yen/％） 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Sales 152,810 159,867 162,999 157,439 633,117 162,010 Matsumoto- kiyoshi 11,783 12,937 14,267 12,753 51,741 12,560 Group Business Segment profit Segment

  12. Slide 12: Quarterly Net Sales and Gross Profit by Product

    【Appendix】 Financial Results for 1Q FY2024 Quarterly Net Sales and Gross Profit by Product FY2023 FY2024 (Millions of yen/％) 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Sales 85,192 91,340 93,264 92,095 361,892 88,378 Medical and pharmaceuti 35,218 40,039 40,416 40,961 156,636 37,069 Segment profit

  13. Slide 13: Cautionary Statement

    Cautionary Statement This document contains future outlooks such as plans, forecasts, strategies, and others which are not historical fact and these are made by the management’s judgement based on the obtainable information at the time of the disclosure. Actual results may significantly differ from

MatsukiyoCocokara & — Q1 FY2024 Earnings Presentation on 6ix